AstraZeneca's acquisition of TeneoTwo will give the company access to its clinical-stage T-cell engager, TNB-486, strengthening their hematological cancer pipeline.

PamGene International BV said on Thursday that it has obtained CE-IVD registration for its IOpener-NSCLC blood test to help guide immunotherapy in advanced-stage cancer patients.

Recently, during the first ZAODX World Cancer Early Screening Conference, Zhu Yeqing, CEO of New Horizon Health Ltd, said that according to CAIVD statistics, there are 58 listed enterprises with IVD business in China by the end of 2021, with a total revenue of 145.032 billion CNY

UK-based startup Tailor Bio has received ￡650,000 ($771,767) through the Innovate UK Biomedical Catalyst Award in support of its ambitions to develop a pan-cancer precision medicine platform.

MirXes, a Singapore-based RNA testing firm, said on Thursday it has signed a memorandum of understanding with several Singapore universities and hospitals to launch a study of circulating microRNA and DNA methylation biomarkers for multi-cancer early detection.

Guardant Health and Chinese clinical laboratory firm Adicon said on Wednesday that they have signed a strategic partnership under which Adicon has licensed Guardant's tissue and blood-based genomic cancer assays

Bio-Techne said on Wednesday that it has recently received CE marking and launched in Europe its assay for human papillomavirus for use in patients with head and neck cancer.

Illumina (Nasdaq:ILMN) announced today that it launched a new research test, co-developed with Merck (NYSE:MRK).

Belgian molecular diagnostics firm Biocartis said on Wednesday that it will develop a molecular test to identify patients with non-small cell lung cancer most likely to respond to AstraZeneca's Tagrisso (osimertinib) treatment.

On June 8, Singlera Genomics (Shanghai) Ltd. (hereinafter referred to as “Singlera Genomics”) announced that it had completed a 300 million CNY B+ round of financing.